Today's Daily Dose brings you news about Amarin's preliminary Q1 revenue; Athersys' initiation of a phase II/III pivotal study of MultiStem therapy in COVID-19-induced acute respiratory distress syndrome; Fennec Pharma's regulatory catalyst in August; initial data of Gilead's Remdesivir in COVID-19 trial and SCWorx' receipt of a purchase order for two million COVID-19 Rapid Tests.
from RTT - Biotech https://ift.tt/3b8ynyf
via IFTTT
No comments:
Post a Comment